Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib versus pirtobrutinib in relapsed or refractory CLL/SLL after prior covalent BTK inhibitor
2026-525656-28-00Phase 3Authorised
- Sponsor
- Newave Pharmaceutical Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Rocbrutinib with Pirtobrutinib (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
rocbrutinibpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2026-525656-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525656-28-00.